Latest Period
Q4 2025
Security Snapshot
LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) Institutional Ownership
CUSIP: 539319301
13F Institutional Holders and Ownership History from Q2 2023 to Q4 2025
Institutions Reporting
17
Shares (Excl. Options)
755,383
Price
$3.93
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- LIXT on Nasdaq
- Shares outstanding
- 2,666,933
- Price per share
- $2.99
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 755,383
- Total reported value
- $2,968,653
- % of total 13F portfolios
- 0%
- Share change
- +316,642
- Value change
- +$1,130,402
- Number of holders
- 17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share is tracked under CUSIP 539319301.
- 17 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 16 to 17 between Q3 2025 and Q4 2025.
- Reported value moved from $2,207,346 to $2,968,653.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 17 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 539319301?
CUSIP 539319301 identifies LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 539319301:
Significant Owners of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTRACOASTAL CAPITAL, LLC | 5% | $181,780 | 138,763 | Mitchell P. Kopin | 11 Feb 2025 | |||
| Orca Capital AG | 4.5% | -45% | $157,216 | -$127,568 | 120,012 | -45% | Orca Capital AG | 14 Feb 2025 |
As of 31 Dec 2025, 17 institutional investors reported holding 755,383 shares of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT). This represents 28% of the company’s total 2,666,933 outstanding shares.
Top 21 Institutional Shareholders
The largest institutional shareholders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) together control 28% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SCOTIA CAPITAL INC. | 9.7% | 258,713 | 0% | $1,016,742 | |
| RENAISSANCE TECHNOLOGIES LLC | 4% | 107,500 | +47% | 0% | $422,475 |
| Federation des caisses Desjardins du Quebec | 3.5% | 93,380 | +84% | 0% | $366,983 |
| VANGUARD GROUP INC | 2.8% | 74,944 | +54% | 0% | $294,530 |
| DRW Securities, LLC | 2% | 54,126 | +12% | 0.02% | $212,715 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 52,163 | +26% | 0% | $204,999 |
| Ethos Financial Group, LLC | 0.93% | 24,808 | 0% | 0.01% | $97,495 |
| STATE STREET CORP | 0.65% | 17,396 | 0% | 0% | $68,366 |
| TWO SIGMA INVESTMENTS, LP | 0.57% | 15,174 | 0% | $59,634 | |
| XTX Topco Ltd | 0.55% | 14,545 | 0% | $57,162 | |
| CITADEL ADVISORS LLC | 0.53% | 14,093 | 0% | $55,385 | |
| AXXCESS WEALTH MANAGEMENT, LLC | 0.52% | 13,771 | 0% | $54,120 | |
| Atlas Legacy Advisors, LLC | 0.52% | 13,771 | 0% | 0.01% | $54,120 |
| UBS Group AG | 0.03% | 756 | -95% | 0% | $2,971 |
| SBI Securities Co., Ltd. | 0.01% | 190 | 0% | 0% | $747 |
| BANK OF AMERICA CORP /DE/ | 0% | 52 | -62% | 0% | $205 |
| CITIGROUP INC | 0% | 1 | -97% | 0% | $4 |
| Tower Research Capital LLC (TRC) | 0% | 0 | -100% | $0 | |
| HighTower Advisors, LLC | 0% | 0 | -100% | $0 | |
| OSAIC HOLDINGS, INC. | 0% | 0 | -100% | $0 | |
| Clear Street Group Inc. | 0% | 0 | -100% | $0 |
Institutional Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 755,383 | $2,968,653 | +$1,130,402 | $3.93 | 17 |
| 2025 Q3 | 438,741 | $2,207,346 | +$1,384,461 | $5.03 | 16 |
| 2025 Q2 | 163,636 | $148,054 | -$163,058 | $0.90 | 10 |
| 2025 Q1 | 300,011 | $384,657 | -$81,359 | $1.21 | 9 |
| 2024 Q4 | 297,557 | $607,533 | +$138,617 | $2.03 | 10 |
| 2024 Q3 | 215,532 | $409,125 | +$72,342 | $1.87 | 7 |
| 2024 Q2 | 178,383 | $424,174 | +$88,625 | $2.37 | 6 |
| 2024 Q1 | 138,296 | $467,369 | +$81,413 | $3.38 | 6 |
| 2023 Q4 | 114,289 | $267,989 | +$177,089 | $2.34 | 6 |
| 2023 Q3 | 37,983 | $92,809 | +$15,777 | $2.45 | 6 |
| 2023 Q2 | 17,340 | $101,452 | +$101,452 | $5.88 | 5 |